<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="90858">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02083653</url>
  </required_header>
  <id_info>
    <org_study_id>EMR200637-002</org_study_id>
    <secondary_id>2013-003829-29</secondary_id>
    <nct_id>NCT02083653</nct_id>
  </id_info>
  <brief_title>Sym004 vs Standard of Care in Subjects With Metastatic Colorectal Cancer</brief_title>
  <official_title>Open-label, Randomized, Controlled, Multicenter Phase II Trial Investigating 2 Sym004 Doses Versus Investigator`s Choice (Best Supportive Care, Capecitabine, 5-FU) in Subjects With Metastatic Colorectal Cancer and Acquired Resistance to Anti-EGFR Monoclonal Antibodies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EMD Serono</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>EMD Serono</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Austria : Federal Ministry for Labour, Health, and Social Affairs</authority>
    <authority>Austria: Agency for Health and Food Safety</authority>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <authority>Germany: Paul-Ehrlich-Institut</authority>
    <authority>Hungary: National Institute for Quality and Organizational Development in Healthcare and Medicines</authority>
    <authority>Italy: The Italian Medicines Agency</authority>
    <authority>Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products</authority>
    <authority>Russia: FSI Scientific Center of Expertise of Medical Application</authority>
    <authority>Russia: Ministry of Health of the Russian Federation</authority>
    <authority>Spain: Agencia Española de Medicamentos y Productos Sanitarios</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2, open-label, 3-arm trial of two Sym004 doses (Arms A and B) and a control
      group (Arm C) in subjects with metastatic colorectal cancer (mCRC) and acquired resistance
      to anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (mAbs).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">July 2016</completion_date>
  <primary_completion_date type="Anticipated">July 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Overall survival (OS) Time</measure>
    <time_frame>Up to 2.5 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>OS time is defined as the time from randomization to the date of death, assessed up to 2.5 years.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Best overall response according to Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST v1.1)</measure>
    <time_frame>From randomization until first radiological confirmed or clinical progression event or death due to any cause within 12 weeks after last tumor assessment, assessed up to 2.5 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS) Time</measure>
    <time_frame>Time from randomization until first radiological confirmed or clinical progression event or death due to any cause within 12 weeks after last tumor assessment, assessed up to 2.5 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to treatment failure</measure>
    <time_frame>Time from randomization to treatment failure or last tumor assessment, assessed up to 2.5 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative dose intensity of Sym004</measure>
    <time_frame>From first dose of study drug until unacceptable toxicity, disease progression, or consent withdrawal, assessed up to 2.5 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters: AUC (0-168 hours), t1/2, CL, Vd, Cmax, tmax and C(trough)</measure>
    <time_frame>Up to Year 2.5</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Host immune response: Number of subjects with anti-drug antibodies (ADAs)</measure>
    <time_frame>Up to Week 24</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers level related to the Epidermal growth factor receptor (EGFR) pathway</measure>
    <time_frame>Screening (Within 14 days prior to Day 1)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life assessed by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Lung Cancer 30 (EORTC QLQ-C30) (Version 3)</measure>
    <time_frame>Every 6 weeks up to 2.5 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life assessed by EORTC QLQ module for colorectal cancer (EORTC QLQ-CR29)</measure>
    <time_frame>Every 6 weeks up to 2.5 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life assessed by Functional Assessment of Cancer Therapy-Epidermal Growth Factor Receptor Inhibitor 18 (FACT-EGFR 18)</measure>
    <time_frame>Every 3 weeks up to 2.5 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with adverse events (AEs), serious AEs, treatment emergent AEs, AEs leading to death, and AEs with National Cancer Institute-Common Terminology Criteria for AEs (NCI−CTCAE Version 4.03) Grade greater than or equal to 3</measure>
    <time_frame>Baseline up to 28 days after the last dose administration or up to 21 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Metastatic Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A: Sym004</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: Sym004</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C: Investigator's choice</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Best supportive care (BSC) or Fluorouracil (5-FU) or Capecitabine will be given as per Investigator's discretion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sym004</intervention_name>
    <description>Sym004 will be administered as an intravenous infusion at a dose of 12 milligram per kilogram (mg/kg) weekly until unacceptable toxicity, disease progression, or consent withdrawal.</description>
    <arm_group_label>Arm A: Sym004</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sym004</intervention_name>
    <description>Sym004 will be administered as an intravenous infusion at a loading dose of 9 mg/kg followed by 6 mg/kg weekly until unacceptable toxicity, disease progression, or consent withdrawal.</description>
    <arm_group_label>Arm B: Sym004</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Best supportive care (BSC)</intervention_name>
    <description>BSC will be provided at the Investigator's discretion and may include antibiotics, analgesics, antiemetics, blood transfusions and nutritional support.</description>
    <arm_group_label>Arm C: Investigator's choice</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluorouracil (5-FU)</intervention_name>
    <description>5-FU will be administered at doses and schedules as per Investigator's discretion and in line with the local package insert.</description>
    <arm_group_label>Arm C: Investigator's choice</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>Capecitabine will be administered at doses and schedules as per Investigator's discretion and in line with the local package insert.</description>
    <arm_group_label>Arm C: Investigator's choice</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent obtained before undergoing any study-related activities

          -  Male or female, at least 18 years of age

          -  Subjects with histologically or cytologically confirmed mCRC, Kirsten rat sarcoma
             wild-type (KRAS WT) at initial diagnosis

          -  Failure of or intolerance to 5-FU, Oxaliplatin, and Irinotecan

          -  Acquired resistance to marketed anti-EGFR mAbs as defined in the protocol

          -  Measurable disease defined as one or more target lesions according to RECIST

          -  Life expectancy of at least 3 months

          -  Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 1

          -  Other protocol defined inclusion criteria could apply

        Exclusion Criteria:

          -  Pretreatment with regorafenib.

          -  Subjects who in the opinion of the subject and investigator would  benefit  more
             from  regorafenib  treatment  (except where regorafenib is not reimbursed in the
             country)

          -  Skin rash Common Terminology Criteria for AEs (CTCAE) Grade greater than 1 from
             previous anti-EGFR therapy at time of randomization

          -  Magnesium less than 0.9 milligram per deciliter (mg/dL)

          -  Known hypersensitivity to any of the treatment ingredients. Known previous Grade 3-4
             infusion related reactions with anti-EGFR mABs

          -  Other protocol defined exclusion criteria could apply
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Responsible</last_name>
    <role>Study Director</role>
    <affiliation>Merck KGaA</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>US Medical Information</last_name>
    <phone>888-275-7376</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Merck KGaA Communication Center</last_name>
    <phone>+49 6151 72 5200</phone>
    <email>service@merckgroup.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Please Contact U.S. Medical Information</name>
      <address>
        <city>Rockland</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>888-275-7376</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Please contact the Merck KGaA Communication Center</name>
      <address>
        <city>Darmstadt</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>+49 6151 72 5200</phone>
      <email>service@merckgroup.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 7, 2014</lastchanged_date>
  <firstreceived_date>March 7, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Metastatic Colorectal Cancer</keyword>
  <keyword>Sym004</keyword>
  <keyword>Best Supportive Care</keyword>
  <keyword>Capecitabine</keyword>
  <keyword>Fluorouracil (5-FU)</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
